Some of the reports about job cuts at Pfizer got it wrong. They said that the cuts were a result of anticipated revenue drops when Lipitor goes generic in 2010. I don't give them that much credit because they’re feeling the pinch now. Merck's Zocor went generic over the Summer and Lipitor is not cost competitive with generic Zocor. So, when Pfizer can't sell their biggest money maker they have to think about cutting overhead.
Add to this the experience of having to pull the statin Torcetrapib from late trials and they're in hot soup.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment